Today, a story about the regulatory challenges behind the Neuralink hype.
FDA Commissioner Marty Makary defended the agency’s recent rejections of rare disease drugs and one of his deputies, Vinay ...
Pharmalittle: We’re reading about Trump’s drug-price claims, a Novo deal for obesity drugs, and more
In his State of the Union address, President Trump claimed he had brought U.S. prescription drug costs from the highest in the world to the lowest ...
Thirty years after scientists demonstrated how brain implants can help rhesus monkeys move robotic limbs using only their ...
Her son Ben, she learned, had mucopolysaccharidosis (MPS) type 2, or Hunter Syndrome, one of a group of rare diseases that is ...
Xenon Pharmaceuticals is developing a drug for the most common type of seizure experienced by people with epilepsy. Here's ...
When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...
“Yuge” news. There’s now a MAHA pill, though the seller took some liberties with the acronym. Send news tips and male-enhancement suggestions to John.Wilkerson@statnews.com or John_Wilkerson.07 on ...
Casey Means, now the epitome of a “MAHA mom," invokes motherhood and “wholeness” in health in making her case to be the U.S.
Vice President JD Vance announced Wednesday that the Trump administration would “temporarily halt” some Medicaid funding to ...
Sarepta's CEO will retire after a tumultuous decade in which Sarepta became a $15 billion company — and then that value ...
The FDA’s recent rejection of a rare disease cell therapy — despite prior internal support and an approval in Europe — is prompting questions about whether the agency’s rhetoric matches its regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results